Logo

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Share this
Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Roche's Tecentriq + Bevacizumab Receive Health Canada's Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Shots:

  • The approval is based on P-III IMbrave150 study assessing Tecentriq (1200 mg) + bevacizumab (15 mg/kg- q3w- IV) vs sorafenib (400mg- bid) in 501 patients in a ratio (2:1) with unresectable or metastatic HCC- prior not treated with systemic therapies
  • Results: 42% reduction in risk of death (OS); 41% reduction the risk of disease worsening or death (PFS); @primary analysis- median survival follow up time (8.6mos.); 7.6mos. delay in median time to deterioration of patient-reported QoL
  • The approval is part of Project Orbis- an initiative of the FDA’s OCE which provides a framework for simultaneous submission and review of oncology products among international partners

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions